Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Biora Therapeutics, Inc.

< Previous 1 2 Next >
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Outlook for 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Submits Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Submit Updated IND Application for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Continues to Monetize Legacy Diagnostics Assets
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Tickers BIOR
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.